BioCryst Pharmaceuticals
BCRX
#4706
Rank
HK$12.52 B
Marketcap
HK$60.49
Share price
1.43%
Change (1 day)
54.61%
Change (1 year)

P/E ratio for BioCryst Pharmaceuticals (BCRX)

P/E ratio as of November 2024 (TTM): -6.23

According to BioCryst Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.228. At the end of 2022 the company had a P/E ratio of -8.63.

P/E ratio history for BioCryst Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-8.63-35.81%
2021-13.494.93%
2020-6.9095.95%
2019-3.52-57.25%
2018-8.2330.82%
2017-6.29-25.42%
2016-8.44-51.75%
2015-17.5-2.19%
2014-17.929.41%
2013-13.8668.76%
2012-1.80-8.31%
2011-1.96-71.18%
2010-6.80-63.14%
2009-18.5775.7%
2008-2.11-69.65%
2007-6.94-9.9%
2006-7.71-53.53%
2005-16.6186.92%
2004-5.78-39.25%
2003-9.51851.39%
2002-1.0000-92.68%
2001-13.7

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
67.8-1,188.08%๐Ÿ‡บ๐Ÿ‡ธ USA
-15.2 144.03%๐Ÿ‡บ๐Ÿ‡ธ USA
-2.47-60.27%๐Ÿ‡บ๐Ÿ‡ธ USA
-1.25-79.99%๐Ÿ‡บ๐Ÿ‡ธ USA
21.9-452.02%๐Ÿ‡บ๐Ÿ‡ธ USA
-10.9 75.48%๐Ÿ‡บ๐Ÿ‡ธ USA
10.4-266.40%๐Ÿ‡ฌ๐Ÿ‡ง UK
-0.9801-84.26%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.9503-84.74%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.